DE10357281A1 - Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating - Google Patents
Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating Download PDFInfo
- Publication number
- DE10357281A1 DE10357281A1 DE2003157281 DE10357281A DE10357281A1 DE 10357281 A1 DE10357281 A1 DE 10357281A1 DE 2003157281 DE2003157281 DE 2003157281 DE 10357281 A DE10357281 A DE 10357281A DE 10357281 A1 DE10357281 A1 DE 10357281A1
- Authority
- DE
- Germany
- Prior art keywords
- vascular support
- coating
- degradation
- vascular
- support according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000015556 catabolic process Effects 0.000 title claims abstract description 35
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 35
- 238000000576 coating method Methods 0.000 title claims abstract description 31
- 239000011248 coating agent Substances 0.000 title claims abstract description 30
- 239000000463 material Substances 0.000 title claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims description 6
- 229910052749 magnesium Inorganic materials 0.000 title claims description 6
- 239000011777 magnesium Substances 0.000 title claims description 6
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 210000004204 blood vessel Anatomy 0.000 title description 3
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 claims abstract description 4
- 229910001635 magnesium fluoride Inorganic materials 0.000 claims abstract description 4
- 230000002792 vascular Effects 0.000 claims description 54
- 230000008859 change Effects 0.000 claims description 8
- 230000035876 healing Effects 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000007943 implant Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010070245 Foreign body Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910000733 Li alloy Inorganic materials 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000001989 lithium alloy Substances 0.000 description 1
- GCICAPWZNUIIDV-UHFFFAOYSA-N lithium magnesium Chemical compound [Li].[Mg] GCICAPWZNUIIDV-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/92—Stents in the form of a rolled-up sheet expanding after insertion into the vessel, e.g. with a spiral shape in cross-section
- A61F2/93—Stents in the form of a rolled-up sheet expanding after insertion into the vessel, e.g. with a spiral shape in cross-section circumferentially expandable by using ratcheting locks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
- A61F2002/30317—The prosthesis having different structural features at different locations within the same prosthesis
- A61F2002/30322—The prosthesis having different structural features at different locations within the same prosthesis differing in surface structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91516—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other the meander having a change in frequency along the band
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0026—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in surface structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0036—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in thickness
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Die Erfindung betrifft eine insbesondere als Stent ausgeführte degradable Gefäßstütze aus einem Magnesiumwerkstoff.The The invention relates to a degradable designed in particular as a stent Vascular support off a magnesium material.
Jährlich erleiden in Deutschland mehrere hunderttausend Menschen einen Herzinfarkt. Es handelt sich hierbei um eine Nekrose eines umschriebenen Herzmuskelbereiches durch schwere Durchblutungsstörungen, welche zumeist ursächlich durch eine Verengung oder den Verschluss eines Herzkranzgefäßes hervorgerufen wird. Diese als Arteriosklerose (Arterienverkalkung) bekannte krankhafte Veränderung arterieller Gefäße äußert sich durch Verhärtung, Verdickung, Elastizitätsverlust und Lichtungseinengung der betroffenen Bereiche.Suffer annually in Germany several hundred thousand people have a heart attack. This is a necrosis of a circumscribed heart muscle area due to severe circulatory disorders, which mostly caused by a constriction or the occlusion of a coronary vessel caused becomes. This is known as arteriosclerosis (arteriosclerosis) pathological change arterial vessels manifests itself Hardening, Thickening, loss of elasticity and clearing of the affected areas.
Gesunde Arterien sind flexibel. Durch falsche Ernährung, mangelnde Bewegung und nicht zuletzt durch den natürlichen Alterungsprozess sammeln sich Fettsäuren, Cholesterin und Kalziumsalze in den Blutgefäßen an. Infolge dessen verlieren die Arterien an Flexibilität, die Gefäßwände verdicken und verengen sich. Der Blutfluss wird zunehmend behindert, was zu einer Mangelversorgung mit Nährstoffen und Sauerstoff führt. An den verengten Gefäßwänden kann es außerdem zu Gerinnungsprozessen kommen. Ein dadurch entstehender Thrombus (Blutgerinnsel) kann das Gefäß vollständig verschließen, wodurch das Herzmuskelgewebe abstirbt und der Infarkt eingeleitet wird.healthy Arteries are flexible. Due to poor diet, lack of exercise and not least by the natural Aging process, fatty acids, cholesterol and calcium salts accumulate in to the blood vessels. As a result, the arteries lose flexibility, thicken the vessel walls and narrow. The blood flow is increasingly hampered, resulting in a Lack of nutrients and oxygen leads. At the narrowed vessel walls can it as well come to coagulation processes. A resulting thrombus (Blood clot) can completely occlude the vessel, causing the heart muscle tissue dies and the infarction is initiated.
Um verengte bzw. verschlossene Gefäße wieder öffnen zu können, wird das betroffene Gefäß häufig durch eine PTCA (percutaneous transluminal coronary angioplasty) mit einer anschließenden Implantation einer Gefäßstütze (Stent) versorgt. Dabei wird das ischämische (blutstauende) Ereignis zunächst durch die Aufweitung eines Ballons, eingeführt über einen Katheder, beseitigt. Plaques und Thromben werden in die Gefäßwand gedrückt und das Lumen erweitert. Zur Offenhaltung des erweiterten Durchmessers wird häufig ein gefäßstützendes Implantat (Stent) ebenfalls über den Katheder in Form eines dünnen, strukturierten Röhrchens eingeführt und an der entsprechenden Stelle erfolgt die Dilatation (Aufweitung) durch einen dehnbaren Ballon. Der Stent wird durch die Vergrößerung seines Durchmessers ohne große Längenänderung an die Gefäßwand gedrückt und stellt den erforderlichen Lumenquerschnitt sicher.Around Reopen closed or closed vessels can, The affected vessel is often through a PTCA (percutaneous transluminal coronary angioplasty) with a subsequent Implantation of a stent provided. This is the ischemic (bleeding) event first by the expansion of a balloon introduced via a catheter. Plaques and thrombi are pushed into the vessel wall and the lumen is dilated. To keep open the extended diameter is often a Vessel-supporting implant (Stent) also over the catheter in the form of a thin, structured tube introduced and dilatation (dilation) takes place at the appropriate place through a stretchable balloon. The stent is enlarged by enlarging its Diameter without big change in length pressed against the vessel wall and ensures the required lumen cross section.
Häufig setzt jedoch aufgrund des eingesetzten Fremdkörpers ein verstärktes Zellwachstum ein. An der Stelle, die ursprünglich verengt war, bilden sich oftmals Zellwucherungen und somit erneute Gefäßverengungen.Often sets However, due to the foreign body used increased cell growth one. In the place, originally was narrowed, often form cell proliferations and thus again Vasoconstriction.
Aufgrund der auftretenden Dehnung sind zudem vermehrt Perforationen von Gefäßen aufgetreten. Dies ist meistens mit einem akuten Schmerz für den Patienten, der bei der Aufdehnung entsteht, verbunden. Außerdem werden die Patienten tachykard und zeigen einen Blutdruckabfall. Zum Verschluss der Perforationsstelle kann es erforderlich werden, weitere Stents zu implantieren, wodurch der Aufwand weiter steigt.by virtue of In addition, the perforation of vessels has increased. This is usually associated with an acute pain for the patient who is at the Stretch arises, connected. In addition, the patients tachycardia and show a drop in blood pressure. For closing the perforation site It may be necessary to implant more stents, thereby the effort continues to rise.
Nach der Implantation der Gefäßstütze muss der Patient wegen des sehr hohen Thrombose-Risikos, das im Stent herrscht, Medikamente zur Verdünnung des Blutes einnehmen, wie beispielsweise Arzneimittel zur Hemmung der Blutplättchenzusammenlagerung.To the implantation of the vascular support must be Patient because of the very high risk of thrombosis, which prevails in the stent, drugs for dilution of the blood, such as drugs for inhibition the platelet aggregation.
Es sind bereits gattungsgemäße Gefäßstützen aus einer Magnesium-Lithium-Legierung bekannt, die sich innerhalb weniger Monate auflösen. Solche Magnesium Gefäßstützen sind vorteilhaft, weil die gefäßstützende Funktion lediglich vorübergehend für wenige Wochen erforderlich ist, jedoch die nachträgliche Entfernung eines einmal implantierten Stent im Allgemeinen ausgeschlossen ist. Magnesium eignet sich besonders für den Stent-Einsatz, weil es problemlos handhabbar ist, keine eigene toxische Wirkung entfaltet und durch die Art der Legierung gesteuert werden kann, wie schnell sich der Stent auflöst. Zudem lassen sich solche Stents auch mit Wirkstoffen beschichten, die das gefäßverschließende Wachstum des Bindegewebes hemmen. Für Kinder entfällt darüber hinaus das nach dem Stand der Technik auftretende Problem herkömmlicher Stents, dass diese durch das Wachstum der Blutgefäße nach einiger Zeit zu klein sind.It are already generic vascular props a magnesium-lithium alloy known to be within less Dissolve months. Such Magnesium stents are advantageous because the vascular supporting function only temporarily for a few Weeks is required, however, the subsequent removal of a once implanted stent is generally excluded. magnesium is particularly suitable for the stent insert, because it is easy to handle, no own toxic effect and controlled by the nature of the alloy can be how fast the stent dissolves. In addition, such can be Stents also coat with active ingredients that block the vaso-occlusive growth of the connective tissue. For children deleted about that addition to the prior art problem of conventional stents, that these become too small due to the growth of the blood vessels after some time are.
Es sind weiterhin auch Gefäßstützen mit unterschiedlichen Beschichtungen bekannt. Beispielsweise sind Versuche unternommen worden, die Gefäßstütze mit Gold zu beschichten, um so eine geringere Restenose-Rate zu erreichen. Weiterhin sind zu diesem Zweck auch Stents bekannt, die mit Phosphorylcholin oder mit Heparin beschichtet sind.It are still also vascular props with different coatings known. For example, experiments taken with the vascular support Coat gold to achieve a lower restenosis rate. Furthermore, stents are known for this purpose, with phosphorylcholine or coated with heparin.
Darüber hinaus wird mit radioaktiven Stents experimentiert, um so durch lokale Strahlentherapie – über einen radioaktiven Drahtanteil oder indem man Radioaktivität direkt über einen Stent platziert – die Restenose-Rate zu vermindern.Furthermore is experimented with radioactive stents, so by local Radiotherapy - over one radioactive wire portion or by radioactivity directly over a Stent placed - the To reduce restenosis rate.
Weiterhin sind auch Stents bekannt, deren Oberfläche mit Medikamenten beschichtet ist. Nach der Stentimplantation werden diese Medikamente freigesetzt, um eine erneute Verengung der Gefäße zu verhindern. Außerdem ist es auch bekannt, Stents mit einer antiproliferativen Substanz zu beschichten und somit die Möglichkeit zu schaffen, die Proliferation der glatten Muskelzelle einzuschränken.Farther Stents are also known whose surface is coated with medication is. After stent implantation, these drugs are released to prevent a renewed narrowing of the vessels. Besides that is It is also known to use stents with an antiproliferative substance coat and thus the possibility to restrict the proliferation of smooth muscle cell.
Der Erfindung liegt die Aufgabe zugrunde, eine Möglichkeit zu schaffen, eine an den medizinischen Heilungsverlauf angepassten Auflösungsprozess der Gefäßstütze zu realisieren.Of the Invention has for its object to provide a way, a adapted to the medical healing process dissolution process to realize the vascular support.
Diese Aufgabe wird erfindungsgemäß mit einer Vorrichtung gemäß den Merkmalen des Anspruchs 1 gelöst. Die Unteransprüche betreffen besonders zweckmäßige Weiterbildungen der Erfindung.These Task is according to the invention with a Device according to the features of claim 1. The dependent claims concern particularly expedient further education the invention.
Erfindungsgemäß ist also eine degradable Gefäßstütze aus einem Magnesiumwerkstoff vorgesehen, die zumindest abschnittsweise mit einer die Degradation verzögernden, biokompatiblen Beschichtung ausgestattet ist. Hierdurch kann der Auflösungsprozess der Gefäßstütze zeitlich derart eingestellt werden, dass die Gefäßstütze den Heilungsprozess optimal unterstützt, insbesondere also die Stützfunktion lediglich solange erfüllt, wie diese aus medizinischer Sicht notwendig oder sinnvoll ist. Die Beschichtung kann dabei in geeigneter Dicke aufgebracht werden. Daher kann ein an den Patienten angepasster, individueller Verlauf der Stützfunktion sowie des Degradationsbeginns eingestellt werden. Die mechanischen Eigenschaften des Grundwerkstoffs der Gefäßstütze bleiben während der Stützphase unverändert und die Degradationsschutzschicht löst sich stetig aber sehr langsam und gleichmäßig auf. Nach der Auflösung der Schutzschicht beginnt die eigentliche Degradation, wobei das Implantat seine mechanischen Eigenschaften verliert und vollständig resorbiert wird.According to the invention is thus a degradable vascular support a magnesium material provided, at least in sections with a delaying the degradation, biocompatible coating is equipped. This allows the resolution process the vascular support in time be adjusted so that the vascular support the healing process optimally support especially the support function only fulfilled as long as how this is necessary or meaningful from a medical point of view. The coating can be applied in a suitable thickness. Therefore, a adapted to the patient, individual course of the support function and the start of degradation. The mechanical Properties of the base material of the vascular support remain during the support phase unchanged and the degradation protective layer dissolves steadily but very slowly and evenly on. To the resolution the protective layer begins the actual degradation, the Implant loses its mechanical properties and completely absorbed becomes.
Dabei erweist es sich als besonders Erfolg versprechend, wenn die Beschichtung als einen wesentlichen Werkstoffbestandteil Magnesiumfluorid aufweist. Hierzu wird auf die unbeschichtete Oberfläche des strukturierten Stents die Beschichtung zur Degradationssteuerung aufgebracht, die auf der Umwandlung der natürlich vorhandenen, oberflächlichen Mischoxidschicht in eine Mischfluoridschicht beruht. Hauptbestandteil dieser Schicht ist insbesondere Magnesiumfluorid und die Nebenbestandteile bestehen aus den Fluoriden der im Grundwerkstoff enthaltenen Legierungselemente. Die Beschichtung wird beispielsweise durch Tauchen in fluoridhaltige Medien mit oder ohne elektrolytische Unterstützung mit einer Beschichtungsstärke bis zu wenigen μm aufgebracht.there proves to be particularly promising if the coating as a material material component magnesium fluoride. This is done on the uncoated surface of the structured stent the coating applied to the degradation control on the transformation of course existing superficial mixed oxide layer is based on a mixed fluoride layer. Main component of this layer is in particular magnesium fluoride and the minor constituents exist from the fluorides of the alloying elements contained in the base material. The coating is, for example, by dipping in fluoride-containing Media with or without electrolytic support with a coverage strength up to to a few microns applied.
Die Beschichtung kann in verschiedenen Bereichen der Gefäßstütze eine homogene Dicke und minimale Rauhigkeit aufweisen, wodurch ein konstanter Auflösungsprozess in der Stützphase erreicht wird, durch den eine optimierte Anpassung an die gewünschten medizinischen Anforderungen sichergestellt wird. Hingegen erweist es sich als besonders praxisnah, wenn die Beschichtung in verschiedenen Bereichen der Gefäßstütze eine unterschiedliche Dicke und/oder Beschaffenheit aufweist. Hierdurch wird ein örtlich unterschiedlicher Auflösungsprozess erreicht, durch den eine weiter optimierte Anpassung an die gewünschten medizinischen Eigenschaften erreicht wird.The Coating can be used in different areas of the vascular support homogeneous thickness and minimal roughness, thereby providing a constant resolution process in the support phase is achieved, through which an optimized adaptation to the desired medical requirements is ensured. On the other hand proves It turns out to be especially practical if the coating is in different areas the vascular support one has different thickness and / or texture. hereby becomes a local different dissolution process achieved by a further optimized adaptation to the desired medical properties is achieved.
Dabei erweist es sich als besonders praxisgerecht, wenn die Beschichtung in verschiedenen Bereichen eine unterschiedliche Dicke und/oder Zusammensetzung aufweist, durch welche eine über den zeitlichen Verlauf der Degradation gezielte Veränderung der Stabilität der Gefäßstütze erreicht wird. Hierdurch wird die Funktionserhaltung derart eingestellt, dass eine individuelle Anpassung an Problemstellung und Anamnesen realisiert werden kann.there proves to be particularly practical if the coating in different areas a different thickness and / or Composition, by which one over the time course the degradation targeted change stability reached the vascular support becomes. As a result, the function maintenance is set such that an individual adaptation to problem statement and medical history can be realized.
Insbesondere wird dabei die Beschichtung in verschiedenen Bereichen derart abweichend ausgeführt, dass aufgrund der Degradation eine Flexibilität der zunächst unbeweglichen Gefäßstütze realisiert ist, um so die Stützfunktion optimal an den Heilungsfortschritt und den dabei aus medizinischer Sicht wünschenswerten Grad der Belastung auf das Gefäß einstellen zu können.Especially In this case, the coating deviates so differently in different areas executed that due to the degradation a flexibility of the initially immovable vascular support is realized so the support function optimal for the healing progress and thereby from medical View desirable Adjust the degree of stress on the vessel to be able to.
Eine weitere besonders Erfolg versprechende Ausgestaltung wird dabei auch dann erreicht, wenn die Beschichtung eine Strukturierung aufweist, so dass aufgrund der abweichenden Degradationseigenschaften Aussparungen und/oder Durchbrechungen der Gefäßstütze entstehen. Hierdurch kann der Herstellungsaufwand wesentlich reduziert werden, indem die gewünschten Durchbrechungen der Gefäßstütze erst durch den Auflösungsprozess entstehen. Das Einsetzen des Stents in das Gefäß wird dadurch erleichtert und Zellwucherungen vermindert. Der Abtransport des beim Auflösungsprozess freigesetzten Wasserstoffgases wird dadurch ebenfalls verbessert.A Another particularly promising embodiment is thereby reached even if the coating has a structuring, so that due to the different degradation properties recesses and / or perforations of the vascular support arise. As a result, the production cost can be significantly reduced by the desired Breakthroughs of the vascular support only through the dissolution process arise. The insertion of the stent into the vessel is thereby facilitated and cell proliferations diminished. The removal of the during the dissolution process released hydrogen gas is thereby also improved.
Dabei zeigt es sich als besonders praxisnah, wenn die Beschichtung entsprechend der durch die Degradation bestimmten, gewünschten Veränderung der äußeren Abmessungen in un terschiedlichen Bereichen abweichend aufgebracht ist. Hierdurch lässt sich in einfacher Weise beispielsweise eine Verkürzung der Länge oder Verringerung des äußeren Durchmessers erreichen.there It turns out to be particularly practical if the coating accordingly the degradation of the outer dimensions determined by the degradation deviated in different areas. hereby let yourself in a simple way, for example, a shortening of the length or reduction of the outer diameter to reach.
Eine individuelle Anpassung an den Patienten wird auch dann erreicht, wenn die Beschichtung entsprechend dem erwartungsgemäßen Heilungsfortschritt aufgebracht ist. Hierzu wird zunächst eine Prognose des zu erwartenden Heilungsfortschrittes in Abhängigkeit der Diagnose erstellt, um so die Art, Stärke und Verteilung der Beschichtung optimal bestimmen und anpassen zu können.A individual adaptation to the patient is also achieved if the coating corresponds to the expected rate of healing is applied. This will be done first a prognosis of the expected healing progress in dependence created the diagnosis, so as to the nature, strength and distribution of the coating optimally determine and adapt.
Besonders Erfolg versprechend ist dabei auch eine Ausgestaltung, bei der die Schicht derart ausgeführt ist, dass während einer ersten Degradationsdauer zunächst keine oder lediglich eine sehr geringfügige Änderung der mechanischen Eigenschaften der Gefäßstütze eintritt, während sich in einer der ersten Degradationsdauer folgenden zweiten Degradationsdauer die mechanischen Eigenschaften insbesondere stetig ändern. Hierdurch wird ein in der medizinischen Praxis bisher nicht erreichbarer Verlauf der Degradation erreicht, der es gestattet, das aus medizinischer Sicht optimale Anforderungsprofil zuverlässig abzubilden und damit den Heilungserfolg wesentlich zu erhöhen. Dabei findet während der ersten Degradationsdauer ein stetiger und langsamer Abbau der Beschichtung statt, welcher durch die Lösung des Beschichtungsmaterials ursächlich herbeigeführt wird. Während dieser ersten Degradationsdauer erfolgt die Endothelialisierung (Neubildung der Gefäßwand mit Endothel-Zellen) und somit das Einwachsen des Implantates, wobei die mechanischen Eigenschaften erhalten bleiben und das Implantat seine Stützfunktion zu 100 % erfüllt. Nach der Endothelialisierung beginnt die zweite Degradationsdauer, wobei sich der Grundkörper des Implantates langsam auflöst und resorbiert wird. Hierbei verliert der Stent stetig seine Festigkeit und das Gefäß kann die Stützfunktion wieder selbstständig übernehmen.Especially Promising is also an embodiment in which the Layer executed in such a way is that while a first degradation period initially no or only one very slight change the mechanical properties of the vascular support occurs while in a second degradation period following the first degradation period In particular, the mechanical properties change constantly. hereby becomes a history not yet attainable in medical practice achieved the degradation that allows it, from medical Viewpoint to optimally depict the optimal requirement profile and thus the Significantly increase healing success. It takes place during the first degradation period a steady and slow degradation of the Coating takes place, which by the solution of the coating material causal brought becomes. While During this first period of degradation, endothelialization takes place (New formation of the vessel wall with Endothelial cells) and thus the ingrowth of the implant, wherein the mechanical properties are preserved and the implant its support function 100% fulfilled. After endothelialization, the second degradation period begins, with the main body of the implant slowly dissolves and reabsorbed. Here, the stent steadily loses its strength and the vessel can support the function take over again independently.
Dabei ist es besonders günstig, wenn während der zweiten Degradationsdauer die Festigkeit stetig abnimmt und dadurch die Gefäßstütze beispielsweise während der ersten Degradationsdauer eine im Wesentlichen konstante Festigkeit aufweist, die während der zweiten Degradationsdauer abnimmt.there is it particularly favorable if during the second degradation period the strength steadily decreases and thereby the vascular support, for example while the first degradation period a substantially constant strength that has during decreases the second degradation period.
Eine weitere besonders gewinnbringende Abwandlung der vorliegenden Erfindung wird auch dadurch erreicht, dass die Gefäßstütze um ihre Längsachse spiralförmig verformbar ausgeführt ist. Hierdurch wird eine optimale Dilatation erreicht. Als Stentgrundkörper kommen dabei beispielsweise spiralförmig einrollbare und insbesondere formschlüssig in der Funktionsstellung festlegbare Formgebungen in Frage.A another particularly profitable modification of the present invention is also achieved by the vascular support around its longitudinal axis spirally deformable executed is. This achieves optimum dilatation. Come as a stent basic body while, for example, spiral rollable and in particular form-fitting in the functional position definable shapes in question.
Weiterhin erweist es sich als besonders zweckmäßig, wenn die Gefäßstütze aus einem laserstrukturierten, rohrförmigen Grundkörper aufgebaut ist, um so eine an die jeweiligen Einsatzbedingungen optimal angepasste Struktur zu erreichen. Die plastischen Verformungszonen sind dadurch nur mit sehr geringen Umformungsgraden belastet. Insbesondere ist die Gefäßstütze derart ausgeführt, dass nach der Aufweitung des Implantates keine oder nur eine sehr geringe Rückfederung (Recoil) auftritt und die Dilatation zu keiner nennenswerten Verkürzung des Stents führt.Farther proves to be particularly useful when the vascular support a laser-structured, tubular body is constructed so as to be optimal for the respective conditions of use to achieve an adapted structure. The plastic deformation zones are thereby burdened only with very low degrees of deformation. In particular the vascular support in such a way executed that after the expansion of the implant no or only a very small rebound (Recoil) occurs and the dilatation does not lead to any appreciable shortening of the Stents leads.
Die Erfindung lässt verschiedene Ausführungsformen zu. Zur weiteren Verdeutlichung ihres Grundprinzips ist eine davon in der Zeichnung dargestellt und wird nachfolgend beschrieben. Diese zeigt inThe Invention leaves different embodiments to. To further clarify its basic principle is one of them shown in the drawing and will be described below. These shows in
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2003157281 DE10357281A1 (en) | 2003-12-05 | 2003-12-05 | Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2003157281 DE10357281A1 (en) | 2003-12-05 | 2003-12-05 | Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10357281A1 true DE10357281A1 (en) | 2005-07-14 |
Family
ID=34672492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2003157281 Ceased DE10357281A1 (en) | 2003-12-05 | 2003-12-05 | Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE10357281A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008051680A2 (en) * | 2006-10-20 | 2008-05-02 | Boston Scientific Limited | Medical device hydrogen surface treatment by electrochemical reduction |
WO2008091835A2 (en) * | 2007-01-26 | 2008-07-31 | Boston Scientific Limited | Implantable medical endoprostheses |
EP2018882A2 (en) | 2007-07-24 | 2009-01-28 | Biotronik VI Patent AG | Endoprosthesis and method for manufacturing the same |
EP1941918A3 (en) * | 2006-12-19 | 2010-05-05 | BIOTRONIK VI Patent AG | Method for manufacturing an anti-corrosive coating on an implant made from a bio-corrodible magnesium alloy and the implant resulting from the method |
EP2189170A1 (en) * | 2008-11-21 | 2010-05-26 | BIOTRONIK VI Patent AG | Method for manufacturing an anti-corrosive coating on an implant made from a bio-corrodible magnesium alloy and the implant resulting from the method |
US7955382B2 (en) | 2006-09-15 | 2011-06-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with adjustable surface features |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US8052744B2 (en) | 2006-09-15 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8128689B2 (en) | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
US8133269B2 (en) | 2007-05-16 | 2012-03-13 | Gelita Ag | Vascular stent |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8303643B2 (en) | 2001-06-27 | 2012-11-06 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
EP2332588A3 (en) * | 2009-12-10 | 2014-01-08 | Biotronik VI Patent AG | Biocorrodible implant having a corrosion-inhibiting coating |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
DE102014105732B3 (en) * | 2014-04-23 | 2015-04-09 | Syntellix Ag | Process for the surface treatment of a biocorrodible implant and implant obtained by the process |
DE102018128206A1 (en) * | 2018-11-12 | 2020-05-14 | Innovent E.V. | Process for producing a magnesium fluoride layer on a magnesium alloy and components produced therewith |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE9103321U1 (en) * | 1991-03-19 | 1992-08-27 | Thera Patent GmbH & Co KG Gesellschaft für industrielle Schutzrechte, 8031 Seefeld | Transparent sealed dental plastic body |
DE19539449A1 (en) * | 1995-10-24 | 1997-04-30 | Biotronik Mess & Therapieg | Process for the production of intraluminal stents from bioresorbable polymer material |
EP0875218A2 (en) * | 1997-04-15 | 1998-11-04 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
DE19856983A1 (en) * | 1998-06-25 | 1999-12-30 | Biotronik Mess & Therapieg | Implantable, bioresorbable vascular wall support, in particular coronary stent |
WO2001041678A2 (en) * | 1999-12-13 | 2001-06-14 | Advanced Cardiovascular Systems, Inc. | Open-celled microcellular polymeric foams for use as vascular grafts and stent covers |
WO2001067991A1 (en) * | 2000-03-13 | 2001-09-20 | Jun Yang | Stent having cover with drug delivery capability |
WO2002013883A2 (en) * | 2000-08-15 | 2002-02-21 | Shayen Medical Ltd. | Drug-eluting membrane for coronary artery stent |
DE10200387A1 (en) * | 2002-01-08 | 2003-08-07 | Translumina Gmbh | Drug delivery stent comprises drug-receiving zones in the form of pores passing through its wall or reinforcements |
WO2004000379A1 (en) * | 2002-06-21 | 2003-12-31 | Advanced Cardiovascular Systems, Inc. | Stent coatings with sustained drug release rate |
-
2003
- 2003-12-05 DE DE2003157281 patent/DE10357281A1/en not_active Ceased
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE9103321U1 (en) * | 1991-03-19 | 1992-08-27 | Thera Patent GmbH & Co KG Gesellschaft für industrielle Schutzrechte, 8031 Seefeld | Transparent sealed dental plastic body |
DE19539449A1 (en) * | 1995-10-24 | 1997-04-30 | Biotronik Mess & Therapieg | Process for the production of intraluminal stents from bioresorbable polymer material |
EP0875218A2 (en) * | 1997-04-15 | 1998-11-04 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
DE19856983A1 (en) * | 1998-06-25 | 1999-12-30 | Biotronik Mess & Therapieg | Implantable, bioresorbable vascular wall support, in particular coronary stent |
WO2001041678A2 (en) * | 1999-12-13 | 2001-06-14 | Advanced Cardiovascular Systems, Inc. | Open-celled microcellular polymeric foams for use as vascular grafts and stent covers |
WO2001067991A1 (en) * | 2000-03-13 | 2001-09-20 | Jun Yang | Stent having cover with drug delivery capability |
WO2002013883A2 (en) * | 2000-08-15 | 2002-02-21 | Shayen Medical Ltd. | Drug-eluting membrane for coronary artery stent |
DE10200387A1 (en) * | 2002-01-08 | 2003-08-07 | Translumina Gmbh | Drug delivery stent comprises drug-receiving zones in the form of pores passing through its wall or reinforcements |
WO2004000379A1 (en) * | 2002-06-21 | 2003-12-31 | Advanced Cardiovascular Systems, Inc. | Stent coatings with sustained drug release rate |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8303643B2 (en) | 2001-06-27 | 2012-11-06 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US8052744B2 (en) | 2006-09-15 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8128689B2 (en) | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
US7955382B2 (en) | 2006-09-15 | 2011-06-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with adjustable surface features |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
WO2008051680A2 (en) * | 2006-10-20 | 2008-05-02 | Boston Scientific Limited | Medical device hydrogen surface treatment by electrochemical reduction |
WO2008051680A3 (en) * | 2006-10-20 | 2009-03-26 | Boston Scient Ltd | Medical device hydrogen surface treatment by electrochemical reduction |
EP1941918A3 (en) * | 2006-12-19 | 2010-05-05 | BIOTRONIK VI Patent AG | Method for manufacturing an anti-corrosive coating on an implant made from a bio-corrodible magnesium alloy and the implant resulting from the method |
US8715339B2 (en) | 2006-12-28 | 2014-05-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
WO2008091835A2 (en) * | 2007-01-26 | 2008-07-31 | Boston Scientific Limited | Implantable medical endoprostheses |
WO2008091835A3 (en) * | 2007-01-26 | 2009-08-06 | Boston Scient Ltd | Implantable medical endoprostheses |
US8133269B2 (en) | 2007-05-16 | 2012-03-13 | Gelita Ag | Vascular stent |
EP2018882A2 (en) | 2007-07-24 | 2009-01-28 | Biotronik VI Patent AG | Endoprosthesis and method for manufacturing the same |
EP2018882A3 (en) * | 2007-07-24 | 2012-12-26 | Biotronik VI Patent AG | Endoprosthesis and method for manufacturing the same |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
EP2189170A1 (en) * | 2008-11-21 | 2010-05-26 | BIOTRONIK VI Patent AG | Method for manufacturing an anti-corrosive coating on an implant made from a bio-corrodible magnesium alloy and the implant resulting from the method |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
EP2332588A3 (en) * | 2009-12-10 | 2014-01-08 | Biotronik VI Patent AG | Biocorrodible implant having a corrosion-inhibiting coating |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
DE102014105732B3 (en) * | 2014-04-23 | 2015-04-09 | Syntellix Ag | Process for the surface treatment of a biocorrodible implant and implant obtained by the process |
WO2015162306A1 (en) | 2014-04-23 | 2015-10-29 | Syntellix Ag | Method for the surface treatment of a biocorrodable implant |
DE102018128206A1 (en) * | 2018-11-12 | 2020-05-14 | Innovent E.V. | Process for producing a magnesium fluoride layer on a magnesium alloy and components produced therewith |
DE102018128206B4 (en) | 2018-11-12 | 2024-09-19 | Innovent E.V. | Process for producing a magnesium fluoride layer on a magnesium alloy and components produced thereby |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10357281A1 (en) | Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating | |
DE69825162T2 (en) | INTRAVASCULAR STENT WITH A DEFLECTION DEVICE | |
DE69029114T2 (en) | Endovascular support device and method | |
EP1419793B1 (en) | Endoprosthesis with a supporting structure of magnesium alloy | |
EP0923389B1 (en) | Metallic implant which is degradable in vivo | |
DE69920185T2 (en) | Device for implanting expandable stents | |
DE69922514T2 (en) | IMPLANT FOR THE MYOCARDIUM | |
DE69924524T2 (en) | INTRAMUSCULAR IMPLANTS | |
DE60212340T2 (en) | GUIDE WIRE DEVICE FOR COMPLETE OCCLUSION | |
EP1314405B1 (en) | Graft with proliferation-inhibiting substance | |
DE69820616T2 (en) | Lumenendoprothese | |
DE102004029611A1 (en) | Implant for e.g. releasing active substances into a vessel through which body fluids flow, comprises a base consisting of a biodegradable material as the carrier of the active substances | |
DE102004043232A1 (en) | Endoprosthesis made of magnesium alloy | |
EP3463206B1 (en) | Vasospasm treatment | |
EP3072463B1 (en) | Medical kit or set for treating a diseased hollow organ | |
DE102004043231A1 (en) | Endoprosthesis made of magnesium alloy | |
DE10107795A1 (en) | Procedure to reduce complications from the implantation of stents | |
DE4336209C2 (en) | Method for producing a vascular prosthesis coated with antithrombotic agents | |
EP1984033B1 (en) | Method for wrapping a stent | |
EP1941950A1 (en) | Method of fabricating porous surfaces on metal components | |
EP1632256A2 (en) | Endoprothesis made of a magnesium alloy | |
WO2007006286A1 (en) | Endovascular implant for occlusion of a blood vessel | |
EP3764928A1 (en) | Thrombectomy device | |
DE10145138B4 (en) | Interventional instrument | |
DE102004062296A1 (en) | Device for positioning a stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8131 | Rejection |